Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart valve design aims to simplify replacements and cut risks

NCT ID NCT04442100

Disease control Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new type of biological heart valve that features an 'easy change' system, designed to make future replacements simpler. Researchers will implant these valves in 500 people with aortic valve disease and track complications like blood clots, infections, and valve wear over time. The goal is to see if the new design improves safety and outcomes compared to standard valves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biological prosthetic heart valves (MedEng-Bio)
What this could lead to
If successful, this could make heart valve replacements easier to perform and reduce serious complications like blood clots or infections.
What could go wrong
This is an early study without a control group, so results may not prove the new valve is better than existing options. Risks include typical surgery complications like bleeding or valve failure over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2016

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. aortic valve disease requiring surgical disease patients without symptoms with severe aortic stenosis - indexed area of the opening less than 0.5 cm2 / m2, average gradient more than 40 mm RT. Art; o patients who require coronary artery bypass grafting with moderate aortic stenosis - indexed area of the hole 0.5 - 1 cm2 / m2, the average gradient is more than 20 mm RT. Art., Regardless of symptoms;patients with symptoms of aortic stenosis, regardless of the severity of stenosis) 2. mitral valve disease requiring surgical disease Exclusion Criteria: 1. the need for prosthetics of two or more valves 2. patients with a decrease in LVEF of less than 45%; 3. the presence of a competing disease or concomitant pathology that significantly affects the prognosis of quality of life or the likelihood of death 4. high pulmonary hypertension (SDJ above 60 mm Hg. Art.); 5. the diameter of the ascending aorta is more than 45 mm; 6. unwillingness of the patient to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve disorder heart valve disorder mitral valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart valve diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    RECRUITING

    Tomsk, Tomsk Oblast, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.